Mr Annaswamy Vaidheesh is the Executive Chairperson of the company with effect from 29th September 2023. As Executive Chairperson, he oversees the company's overall business operations.
Mr. Vaidheesh is a successful senior business leader from the most admired Fortune 100 companies with more than 35 years of diverse experience in the healthcare and FMCG Industry, including at Johnson and Johnson, Pfizer and GSK. He has proven expertise in general management with a strong background in market creation and leadership development. Further, he has rich experience in building strong leadership for brands/franchises across varied categories (healthcare and FMCG) and in multi-grid and multi-cultural Locations in the Asia-Pacific region.
Prior to his current roles, Mr Vaidheesh has amassed a wealth of experience in the industry. He held significant positions, including the President of OPPI (Organization of Pharmaceutical Producers of India) and Chairman of various committees and councils of Industry bodies in India and the region. He was recognised by various prestigious organisations like the Economic Times for his leadership capabilities.
Additionally, he has served as an operating partner with Advent International.
Dr. V. Prasada Raju is the Company's Managing Director, appointed on 29th September 2023. Dr Prasada Raju is also CEO and MD of Cohance Lifesciences Ltd.
Dr Prasada Raju served as an Executive Director at Granules India Ltd., where he played a key role in driving growth strategy, managing the product portfolio, overseeing scientific and regulatory affairs, handling intellectual property matters, and leading new business initiatives. Moreover, he was instrumental in establishing R&D and Greenfield projects within the company. As part of his responsibilities, he served on the Boards of Granules Omnichem Pvt Ltd (Vizag, India), Granules Pharmaceuticals Inc. (DC, USA), and USpharma Ltd (FL, USA).
Dr Prasada Raju's impressive academic background includes a PhD in chemistry, a PG Dip in patent law, and specialised training in material sciences at IIT, Chicago, USA. He is also an alumnus of the Senior Management Program at IIMC (Indian Institute of Management). With over 30 years of techno-commercial experience in the pharmaceutical industry, spanning various aspects of the value chain, he has held leadership roles at Granules India Limited and Dr Reddy's Laboratories. During his tenure at Dr. Reddy's, from 1994 to 2012, he provided technical, strategic, and operational leadership in uniquely challenging positions within the pharma sector.
Overall, Dr V. Prasada Raju's extensive experience and expertise make him a highly respected and accomplished figure in the pharmaceutical industry, where he continues to make significant contributions in his current roles.
Mr Pankaj Patwari is a Non-Executive Director of the Company, effect from 29th September 2023. He is a Chartered Accountant by training and holds an MBA from the Indian Institute of Management (Lucknow).
As Managing Director - of Advent India PE Advisors Private Limited, he has managed Advent's investments in Manjushree Technopack Limited and Bharat Serums and Vaccines Limited (BSV). He has also been a Director at Manjushree Technopack Limited and Gokaldas Intimatewear Private Limited.
Having worked with Bain Capital before Advent for six years, Pankaj worked on several pharmaceutical and industrial transactions. Before his stint at Bain, Pankaj spent four years with McKinsey & Co., focusing primarily on financial services.
Mr. K G Ananthakrishnan is an Independent Director of the Company with effect from 29th September 2023. Throughout his illustrious career, Mr Ananthakrishnan has held influential positions, including Director General of the Organization of Pharmaceutical Producers of India (OPPI) and Co-Chair of the Pharma Committee at the Confederation of Indian Industry (CII), where he played a pivotal role in shaping vital policy initiatives.
Educationally, Mr Ananthakrishnan holds a Master's in Marketing Management from Jamnalal Bajaj Institute of Management Studies, Mumbai, and a Bachelor's in Science from Osmania University, Hyderabad. To further enhance his knowledge and skills, he has completed Executive Development Programs at the Wharton Business School, USA, and the Finance for Non-Finance Program at INSEAD, France.
With over 40 years of progressive leadership experience in the pharmaceutical market, Mr. Ananthakrishnan’s career began in 1976 with Novartis India Limited. He then held key positions at Pharmacia India, Pfizer India Ltd., and Fulford (India) Ltd. Notably, during his tenure as Vice President and Managing Director of the South Asia Region at MSD, he successfully transformed the company into a rapid-growth pharmaceutical powerhouse.
Ms Matangi Gowrishankar is an Independent Director of the Company with effect from 29th September 2023. She is a distinguished expert, serving as a Strategic Advisor, Certified Coach, and Catalyst for change. Prior to her current role, Ms Gowrishankar held the esteemed position of BP's Global Head of Capability Development, where she played a crucial role in enhancing the organisation's talent capabilities and driving leadership excellence.
With over 40 years of experience working with senior leadership teams, Ms Matangi Gowrishankar brings knowledge and insights to support organisations' growth and transformation endeavours. Her extensive Business and Human Resources professional background has provided her invaluable global exposure and a deep understanding of various leadership aspects.
Having closely collaborated with Senior Leadership teams, Ms Gowrishankar possesses valuable expertise in emerging skills such as Contemporary Leadership, Leading in a digitally enabled world, and leadership transformation. She collaborates closely with organisations to develop leadership capabilities that align with the demands of a rapidly evolving business landscape, ensuring sustainable success and growth. As an Independent Director, she contributes her wealth of experience and strategic guidance to the Company, playing a significant role in its development and progress.
Mr Vinod Rao is an Independent Director of the Company with effect from 29th September 2023. Currently, he is also a Director at Eureka Forbes. Mr Rao has held senior roles at renowned organisations such as Diageo (FTSE 10), PepsiCo (S&P 100), and ICI (formerly FTSE 100).
Over 35 years of expertise spans various industries, including FMCG, consumer durables, and industrial products.
Throughout his career, Mr Rao has developed a deep understanding of developing and developed markets, including India, China, Southeast Asia, the UK, and Europe. This global exposure has enabled him to navigate diverse business environments and contribute valuable insights to organisations operating in different regions.
Mr Pravin is an Independent Director of the company, with effect from 9th November 2023. He has done his bachelor’s degree in Electrical Engineering from Bangalore University and comes with 35+ years of rich experience. He started as a software engineer trainee with Infosys in 1986 and superannuated as Chief Operating Officer and Member of Board in Dec’22. He acts as independent director at Axis Finance Limited, Indegene Pvt Ltd, Zensar Technologies Ltd.
Ms Shweta Jalan is a Non-Executive Director of the Company, with effect from 9th November 2023. She has been Managing Director with Advent India PE Advisors Private Limited (Advent) since 2009.
Before joining Advent, she worked with ICICI Venture, India's largest private equity firm. Before that, she had spent a year with the corporate finance division of Ernst & Young. She is also a Director at Dixcy Textiles Private Limited and Manjushree Technopack Limited.
Shweta has experience sourcing and negotiating transactions and has worked across various sectors, including industrial, media, business services, and IT/BPO. She also offers counsel on managing investments and planning successful exits, viz., sales to strategic buyers and listing companies.
Dr Sudhir Kumar Singh is the Chief Executive Officer of the Company, appointed on 29th September 2023.
Dr Singh's academic background includes a PhD in Medicinal Chemistry from one of India’s premier research organisations, Central Drug Research Institute, followed by a post-A doctoral fellowship in the USA and a faculty member at Rutgers University, New Jersey, with over three decades of experience in the pharmaceutical and biotech industry. He has served as the Chief Operating Officer at Aragen Life Sciences Ltd. Dr Singh led a team of 2000 scientists in India's largest Contract Development and Manufacturing Organization (CDMO). His strategic guidance and exceptional project management have driven the organisation's growth and success.
With a strong drug discovery and development background, evidenced by his significant research contributions and patented innovations, Dr Singh has played a crucial role in advancing drug development efforts within the industry.
Mr Gaurav Bahadur is the Chief Human Resources Officer of the company. He was appointed on 29 September 2023. He is responsible for overseeing and managing various aspects of the human resources function within the company.
Gaurav has held leadership roles in renowned companies such as Vodafone Essar, Yahoo! India, and Philips India. His transformative tenure at Sanofi India, where he spearheaded strategic HR initiatives, showcases his expertise in building performance-driven cultures. Gaurav holds a Master’s Degree in Personnel Management from Symbiosis Institute of Business Management and a Bachelor's Degree in Chemistry from St. Xavier's College, Mumbai. Join us in welcoming Gaurav Bahadur to our team.
Mr Raju Komaravolu is the Chief Strategy Officer of the Company. He was appointed on 29th September 2023. He is responsible for the Company's overall Strategic choice-making, Investor Relations, M&A Integration, Strategic Marketing and Transformation agenda.
Raju has a B Tech from NIT Warangal and an MBA from IIM Ahmedabad and has worked for ITC Ltd, McKinsey & Co. and Dr Reddy’s Labs Ltd.
Raju brings over 26 years of multi-industry experience across Strategy, Sales, Marketing, Manufacturing, and Project Management. Raju held several P&L leadership roles during the last five years at Dr Reddy’s. His leadership strengths lie in strategy development and strong execution.
Mr Brian Shaughnessy is the Chief Commercial Officer of the Company. Brian is responsible for leading and managing all aspects of the Company’s commercial initiatives and activities, including sales, marketing, and business development functions.
Brian has a BS in Chemical Engineering from Villanova University and has 20+ years of experience in the CDMO and life science industries. He has held various positions of increasing responsibility with companies, including Aragen (formerly GVK BIO), Piramal, Dr Reddy’s, and Johnson Matthey.
Brian is passionate about developing highly motivated teams that focus on cultivating trusted relationships with client partners by providing reliable and value-added solutions.
Mr. P.S. Rao is the CFO of the company joined in June 1995.
Mr. Rao is qualified CMA, Commerce graduate from a college of Andhra University, stood second in college.
Before joining SUVEN group, he started his career as account’s assistant during the year 1978 and joined in a pharma company by name STANDARD ORGANICS LIMITED, the first API manufacturing company, based at Hyderabad till March 1990. Later joined Dr Reddy’s Laboratories Ltd during April 1990 and worked till June 1995, in charge of the Diagnostic Division of the DRL group.
He later joined SUVEN group on 5th June’1995 involved in the SUVEN’s group growth from a small turnover of Rs.6.00 Crs (FY-1994) to current Rs.1386.00 Crs with an EBITA around 45%. During his tenure handled IPO, floating of several group companies, mergers, de-mergers and implementing good IFCs by way of various ERPs as well as successfully implementing the SAP. Participated in Capacities expansion through the acquisition of sick units from financial institutions/banks by participating auctions, all the units except the Vizag facility, which has been a greenfield one. Maintained financial discipline with conservative approach for taking loans and maintained most of the years with zero debt by considering liquid net assets. And mastered in investing the surplus money in debt mutual funds in the range of Rs.200 to 600 Crs for a period of almost last 5 to 6 years.
Mr. Venkateswarlu Jasti holds a postgraduate degree in Pharmacy from Andhra University, Visakhapatnam, and St. John University, New York, specializing in Industrial Pharmacy.
Mr. Jasti is a highly accomplished individual with a strong background in pharmacy and business. He has pioneered CRAMS business model in India. He founded Suven Pharma Ltd and Suven Life Sciences Limited and successfully led the company since its inception in 1989. Under his leadership, Suven Life Sciences Limited has developed innovative business models and initiated discovery programs resulting in a pipeline of 13 molecules, including SUVN-502, currently undergoing a Phase 3 study in the USA for Agitation in Alzheimer's disease and completed SUVN-G3031, Phase 2 study targeted treatment for Narcolepsy, excessive day time sleep disorder. Mr Jasti has also played vital roles in forming the A.P. Chief Minister's task force for Pharma, the establishment of Pharma City in Vishakhapatnam, and the creation of PHARMEXCIL. He has held significant leadership positions in industry associations such as the Indian Pharmaceutical Association and the Bulk Drug Manufacturers Association of India.
He is a recognized biotech leader with more than 40 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. He recently served at Editas Medicine, a clinical-stage biotechnology company, Board of Directors as Chairman from March 2018 until February 2021 when was appointed as President and CEO. In June 2022, Jim became Editas Executive Chairman until May 2023. Previously, he served as Chief Executive Officer of Patheon NV, a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific, Inc. (Thermo Fisher), in August 2017. Before joining Patheon, Jim served as Chief Executive Officer and President at Biogen, Inc. (Biogen), one of the world’s largest biotechnology companies. Prior to being named Chief Executive Officer, he held various operating positions at Biogen, including Chief Operating Officer, Vice President, International, and Vice President, Operations.
Jim also serves on the Board of Directors of Thermo Fisher Scientific. He previously served on the Board of Directors of Patheon, Biogen, Insulet and PerkinElmer, Inc. He was also Chairman of the Board of Directors of the Biotechnology Innovation Organization.
Jim holds a BS in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.
Mr Stefan Stoffel is an Advisor of the Company with effect from October 2023. Mr Stoffel is a highly accomplished professional, holding a degree in engineering from Lucerne University of Applied Sciences and Arts (CH). With over 35 years of experience, he has demonstrated expertise in production engineering, plant operations, and supply chain management. Stoffel's exceptional track record, coupled with his experience as the former COO of Lonza, highlights his ability to manage complex operations and successfully navigate the demands of the industry.
Mr Stoffel has held significant roles throughout his career, including Head of Lonza Pharma & Biotech Strategic Growth Investments and Ibex Solutions, Head of Lonza Pharma & Biotech Operations, and General Manager of Lonza Chemical Operations Business Unit.
Abhijit Mukherjee has joined Advisory council effective October 2023. A chemical engineer from IIT-Kharagpur, Mr. Mukherjee superannuated from Dr. Reddy’s in March 2018 after playing varied senior roles there for 15 years; the last stint at Dr. Reddy’s was as COO from 2014 to 2018.
Mr. Mukherjee had worked with Hindustan Unilever Ltd for 13 years and with Atul Limited for nine years. Apart from serving on the board of Bharat Serums and Vaccines Limited and ZCL Chemicals Limited, Mr. Mukherjee is on the board of ICE in Milan, Italy.
World class manufacturing facilities in the business of Pharmaceuticals and Fine Chemical Intermediates for Global Pharma Companies for New Chemical Entities (NCE’s) as the thrust area.